Opus Genetics, Inc. (IRD)
NASDAQ: IRD · Real-Time Price · USD
1.270
-0.010 (-0.78%)
At close: Sep 5, 2025, 4:00 PM
1.280
+0.010 (0.79%)
Pre-market: Sep 8, 2025, 8:35 AM EDT
Opus Genetics Revenue
Opus Genetics had revenue of $2.88M in the quarter ending June 30, 2025, with 159.17% growth. This brings the company's revenue in the last twelve months to $15.42M, down -6.25% year-over-year. In the year 2024, Opus Genetics had annual revenue of $10.99M, down -42.30%.
Revenue (ttm)
$15.42M
Revenue Growth
-6.25%
P/S Ratio
3.17
Revenue / Employee
$856,722
Employees
18
Market Cap
80.07M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 10.99M | -8.06M | -42.30% |
Dec 31, 2023 | 19.05M | -20.80M | -52.20% |
Dec 31, 2022 | 39.85M | 39.26M | 6,665.70% |
Dec 31, 2021 | 589.00K | - | - |
Dec 31, 2020 | - | - | - |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
IRD News
- 4 days ago - Opus Genetics Doses First Patient in Pivotal LYNX-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients With Visual Disturbances Under Mesopic, Low-Contrast Conditions - GlobeNewsWire
- 5 days ago - Opus Genetics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference - GlobeNewsWire
- 6 days ago - Opus Genetics Appoints Rob Gagnon as Chief Financial Officer - GlobeNewsWire
- 12 days ago - Opus Genetics Inherited Retinal Disease Programs Featured at Medical and Industry Conferences in September - GlobeNewsWire
- 21 days ago - Opus Genetics Announces FDA Clearance of IND Application for Gene Therapy Candidate OPGx-BEST1 - GlobeNewsWire
- 25 days ago - Opus Genetics Announces Financial Results for Second Quarter 2025 and Provides Corporate Update - GlobeNewsWire
- 4 weeks ago - Opus Genetics to Participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference - GlobeNewsWire
- 6 weeks ago - Opus Genetics and the Global RDH12 Alliance Partner to Advance RDH12 Gene Therapy for Inherited Childhood Blindness - GlobeNewsWire